Mexiletine
Spinal and Bulbar Muscular Atrophy
Masahisa KatsunoSmall moleculePhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Spinal and Bulbar Muscular Atrophy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Zoladex Ramathibodi Hospital | Phase 4 | BB |
bvs857 Novartis Pharmaceuticals | Phase 2 | B |
TESTOSTERONE UNDECYLATE National Center for Research Resources (NCRR) | Phase 2 | B |
LEUPROLIDE National Center for Research Resources (NCRR) | Phase 2 | B |
Nido-361 Nido Biosciences, Inc. | Phase 2 | B |
AVOLVE National Institute of Neurological Disorders and Stroke (NINDS) | Phase 2 | B |
Clenbuterol Gianni Soraru | Phase 2 | CCC |
aj201 AnnJi Pharmaceutical Co., Ltd. | Phase 1/2 | CCC |
Same molecule, other indications
Mexiletine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →